{"symbol":"AMGN","fiscalQuarter":"Q2-2026","reportDate":"2026-08-04","reportTime":"AMC","status":"upcoming","company":{"name":"Amgen Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/AMGN/earnings/Q2-2026","estimates":{"consensusEps":5.6183,"consensusRevenue":9423.04,"epsLow":4.99,"epsHigh":6.28,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Amgen Inc. is a leading biotechnology company in the health care sector that focuses on developing innovative therapies for serious illnesses. With a market cap of $209 billion, Amgen plays a significant role in advancing medical science and improving patient outcomes through its research and development efforts.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a key indicator of profitability and reflects the company's financial health.","consensus":"$5.62"},{"name":"Revenue","why":"Revenue growth is crucial for assessing the company's ability to expand its market presence and support future innovations.","consensus":"$9.4B"}],"lastQuarterRecap":{"summary":"In Q1-2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. This positive surprise contributed to a 2.43% increase in stock price the following day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Amgen to report solid earnings driven by strong product demand, with a consensus EPS of $5.62 and revenue of $9.4 billion.","bullCase":"If Amgen beats expectations, it could signal robust demand for its therapies, potentially leading to increased investor confidence and a positive stock reaction.","bearCase":"Conversely, if the company misses estimates, it may raise concerns about its growth prospects and lead to a negative stock reaction."},"optionsSignal":{"impliedMove":"3.48%","context":"The options market is pricing in a move of approximately 3.48%, indicating that traders expect some volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+8.88%","reaction":"+2.43%"},{"quarter":"Q4-2025","epsSurprise":"+11.18%","reaction":"-1.77%"},{"quarter":"Q3-2025","epsSurprise":"+12.75%","reaction":"+0.13%"},{"quarter":"Q2-2025","epsSurprise":"+15.61%","reaction":"-0.62%"},{"quarter":"Q1-2025","epsSurprise":"+17.85%","reaction":"-2.45%"}],"pivotalQuestions":[{"question":"Will Amgen's EPS exceed the consensus estimate of $5.62?","whyItMatters":"A beat on EPS could indicate stronger-than-expected demand for its products and boost investor confidence."},{"question":"What guidance will Amgen provide for future revenue growth?","whyItMatters":"Future revenue guidance will be critical for assessing the company's growth trajectory and market position."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $5.75 or higher would confirm strong demand and positive momentum.","bearTrigger":"An EPS below $5.50 could signal weakening performance and concerns about future growth.","context":"The market is focused on Amgen's ability to maintain its growth trajectory amidst competitive pressures and market dynamics."},"scenarioPlaybook":{"beatAndRaise":"If Amgen beats expectations, history suggests a potential average one-day move of +2.43%, confirming strong demand.","inLineCautious":"If results are in line with expectations, the stock may see muted reactions as investors await further clarity on guidance.","miss":"A miss on earnings could lead to a decline, with history indicating an average one-day move of -2.45% when expectations are not met."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The consensus may be underestimating Amgen's ability to leverage its recent product launches, which could drive higher-than-expected revenue growth.","supportingPoints":["Amgen has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.","The options market is pricing a move that is higher than the historical average, suggesting that traders expect significant volatility."],"riskToConsensus":"If Amgen's revenue growth exceeds $9.6 billion, it could challenge the current bearish sentiment."},"whatToListenFor":["Any updates on new product launches and their market reception.","Details on cost management and pricing strategies in response to competition.","Insights into pipeline developments and upcoming clinical trials.","Management's outlook on market conditions and competitive landscape.","Any commentary on regulatory changes that could impact operations."],"metaDescription":"Amgen (AMGN) reports Q2 2026 earnings August 4. Analysts expect $5.62 EPS on $9.4B revenue. Here's what to watch."}}